Literature DB >> 8973996

Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers.

S Liao1, M Palmer, C Fowler, R K Nayak.   

Abstract

Some fluoroquinolone drug-drug interactions involving inhibition of the hepatic metabolism of agents such as theophylline and caffeine have been identified. This study was designed to investigate the potential interaction of the fluoroquinolone levofloxacin in a standard multiple-dose regimen with the oral anticoagulant warfarin. Sixteen healthy male volunteers were given a single oral dose of 30 mg warfarin sodium during a multiple-dose regimen of placebo or levofloxacin 500 mg twice daily, in a placebo-controlled, randomized, double-blind, two-way crossover design. Plasma R(+) and S(-) warfarin concentrations and prothrombin times were measured for 6 days after administration of each warfarin dose. The pharmacokinetic parameters of both enantiomers of warfarin were comparable in the absence and presence of levofloxacin, with no significant differences noted in warfarin peak plasma concentration, time to peak plasma concentration, apparent total body clearance, and terminal disposition half-life. Levofloxacin also had no significant effect on warfarin pharmacodynamics, as assessed by baseline-corrected maximum prothrombin time, time to maximum prothrombin time, and area under the prothrombin time-versus-time curve. The lack of pharmacokinetic or pharmacodynamic interaction observed in this study suggests that a clinically important effect of levofloxacin on warfarin is unlikely to occur during concurrent therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8973996     DOI: 10.1177/009127009603601111

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

1.  Levofloxacin-warfarin interaction.

Authors:  G Gheno; L Cinetto
Journal:  Eur J Clin Pharmacol       Date:  2001-08       Impact factor: 2.953

Review 2.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

4.  The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.

Authors:  Jeffrey J Glasheen; Randolph V Fugit; Allan V Prochazka
Journal:  J Gen Intern Med       Date:  2005-07       Impact factor: 5.128

5.  Drug interactions with clinafloxacin.

Authors:  E J Randinitis; C W Alvey; J R Koup; G Rausch; R Abel; N J Bron; N J Hounslow; A B Vassos; A J Sedman
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

Review 6.  A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.

Authors:  S J Martin; R Jung; C G Garvin
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 7.  Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.

Authors:  H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

8.  Retrospective assessment of potential interaction between levofloxacin and warfarin.

Authors:  Gabriel Mercadal Orfila; Berta Gracia García; Elisabet Leiva Badosa; María Perayre Badía; Concepción Reynaldo Martínez; Ramón Jodar Masanés
Journal:  Pharm World Sci       Date:  2008-12-06

9.  Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients.

Authors:  Yuanyuan Wang; Muh Akbar Bahar; Anouk M E Jansen; Janwillem W H Kocks; Jan-Willem C Alffenaar; Eelko Hak; Bob Wilffert; Sander D Borgsteede
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.